Q1 EPS Estimate for Halozyme Therapeutics Lowered by Analyst

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) - Investment analysts at Zacks Research decreased their Q1 2025 earnings estimates for shares of Halozyme Therapeutics in a report issued on Wednesday, February 5th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will earn $0.93 per share for the quarter, down from their prior estimate of $0.98. The consensus estimate for Halozyme Therapeutics' current full-year earnings is $3.87 per share. Zacks Research also issued estimates for Halozyme Therapeutics' Q4 2025 earnings at $1.60 EPS, FY2025 earnings at $4.72 EPS, Q2 2026 earnings at $1.42 EPS, Q3 2026 earnings at $1.40 EPS and FY2026 earnings at $6.02 EPS.

Other equities analysts have also issued reports about the company. Piper Sandler boosted their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a research report on Friday, January 10th. Cowen reaffirmed a "buy" rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. HC Wainwright reissued a "buy" rating and set a $70.00 price target on shares of Halozyme Therapeutics in a research report on Tuesday, February 4th. JMP Securities lifted their target price on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a "market outperform" rating in a report on Friday, November 1st. Finally, Wells Fargo & Company lowered their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a report on Monday, January 13th. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $60.89.

Halozyme Therapeutics Trading Up 0.9 %

Shares of Halozyme Therapeutics stock traded up $0.50 during trading on Monday, reaching $58.61. 883,110 shares of the company were exchanged, compared to its average volume of 1,272,773. The business has a 50-day moving average price of $52.09 and a 200-day moving average price of $54.45. The firm has a market capitalization of $7.46 billion, a price-to-earnings ratio of 19.41, a P/E/G ratio of 0.44 and a beta of 1.25. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. Halozyme Therapeutics has a twelve month low of $34.70 and a twelve month high of $65.53.

Insider Buying and Selling at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 5,000 shares of the business's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $56.30, for a total transaction of $281,500.00. Following the transaction, the director now directly owns 38,611 shares in the company, valued at approximately $2,173,799.30. The trade was a 11.46 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 2.40% of the company's stock.

Institutional Investors Weigh In On Halozyme Therapeutics

Several hedge funds have recently bought and sold shares of HALO. Smartleaf Asset Management LLC lifted its position in shares of Halozyme Therapeutics by 29.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock valued at $42,000 after buying an additional 197 shares during the last quarter. Louisiana State Employees Retirement System raised its position in shares of Halozyme Therapeutics by 0.6% in the fourth quarter. Louisiana State Employees Retirement System now owns 35,300 shares of the biopharmaceutical company's stock valued at $1,688,000 after buying an additional 200 shares in the last quarter. Verdence Capital Advisors LLC grew its holdings in shares of Halozyme Therapeutics by 1.9% during the 3rd quarter. Verdence Capital Advisors LLC now owns 13,232 shares of the biopharmaceutical company's stock worth $757,000 after purchasing an additional 252 shares in the last quarter. CreativeOne Wealth LLC increased its holdings in Halozyme Therapeutics by 1.6% in the 4th quarter. CreativeOne Wealth LLC now owns 18,383 shares of the biopharmaceutical company's stock valued at $879,000 after buying an additional 294 shares during the period. Finally, State of New Jersey Common Pension Fund D raised its position in Halozyme Therapeutics by 0.6% during the fourth quarter. State of New Jersey Common Pension Fund D now owns 47,663 shares of the biopharmaceutical company's stock valued at $2,279,000 after purchasing an additional 302 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.